Morrisville

Avelo Airlines Opens 5th Base in Raleigh-Durham

Retrieved on: 
Wednesday, February 15, 2023
Well, Aircraft, TSA, Terminal One, The Mothership Connection – Live from Houston, Morrisville, Raleigh–Durham International Airport, Flight, Customer, Crew, Heathrow Terminal 2, Travel, RDU, Boeing, Airport, Culture, Atmosphere, Triangle, Town, Partnership, Air travel, Research Triangle, Tweed New Haven Airport, Airline, Tourism, Avelo Airlines, Maintenance, Aircraft pilot

RDU AIRPORT, N.C., Feb. 15, 2023 /PRNewswire/ -- Avelo Airlines opened its fifth base today at Raleigh-Durham International Airport (RDU). The new base enables Avelo to significantly expand the affordable, convenient and reliable air service the airline introduced to North Carolina's Research Triangle region last May.

Key Points: 
  • RDU AIRPORT, N.C., Feb. 15, 2023 /PRNewswire/ -- Avelo Airlines opened its fifth base today at Raleigh-Durham International Airport (RDU).
  • Avelo Airlines Chairman and CEO Andrew Levy said, "Since taking flight at RDU last May, we have been very encouraged by the positive response Avelo has received from Raleigh, Durham and the surrounding areas.
  • The opening of our fifth base at RDU marks an important milestone for Avelo and access for The Triangle Region to six new nonstop Florida routes.
  • With the debut of Avelo's new base, Avelo now serves seven nonstop destinations from RDU, including six new popular Florida routes.

Data443 Announces the Appointment of Nanuk Warman as Chief Financial Officer

Retrieved on: 
Thursday, December 9, 2021
XRP, SEC, Monitoring, IFRS, PARK, Coronavirus, Privacy, World, LGPD, Annual report, Compliance, Disclosure, ATDS, Ripple, GLOBE, Global Privacy Enforcement Network, Knowledge, Resilience, Private Securities Litigation Reform Act, Industry, Organization, PCI, Risk, CCPA, Nanook, Infection, GDPR, RESEARCH, U.S. Securities and Exchange Commission, Solution, Company, CFA, Growth, Security (finance), Name, Access control, Security, Software, World Health Organization, PII, Software as a service, Salesforce, III, Degenerative disease, GAAP, CMA, WordPress, Pub, Microsoft OneDrive, CPA, PI, COVID-19, Medical device, Risk management, Video game console

(Data443 or the Company) (OTCPK: ATDS), a leading data security and privacy software company, today announced the appointment of Nanuk Warman as Chief Financial Officer.

Key Points: 
  • (Data443 or the Company) (OTCPK: ATDS), a leading data security and privacy software company, today announced the appointment of Nanuk Warman as Chief Financial Officer.
  • Additionally, Mr. Warman has worked with the Company for almost three years as an independent consultant and has extensive knowledge of the Companys financial history and business.
  • Mr. Warman founded PubCo Reporting Solutions in 2010 and has significant experience dealing with complex financial reporting requirements under US GAAP and IFRS.
  • Jason Remillard, Data443s Founder and Chief Executive Officer, commented, Nanuk is a high caliber addition to Data443, possessing the skill set, experience, and intimate knowledge of our Company critical to our success at this inflection point.

Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Retrieved on: 
Tuesday, November 30, 2021
Patient, Private Securities Litigation Reform Act, Defense, Sale, B cell, Peptide, Safety, Time, NIH, Nasdaq, Company, Cancer, Severe acute respiratory syndrome coronavirus 2, Heat Biologics, SEC, Mass, Vaccine, COVID-19, Weapon, Annual report, Mouse, Omicron, Research, Investment, GLOBE, Malaria, Marketing, Terminology, Knowledge, OX40L, Form 10-K, Infection, Immune system, Maintenance, Congress, NASDAQ, DOD, Growth, Pathogen, Pharmaceutical industry

DURHAM, N.C., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today unveiled its new RapidVax® cellular vaccine platform at the 2021 World Antiviral Congress. RapidVax is designed as a rapid programmable vaccine to target a comprehensive range of emerging biological threats. Heat is showcasing a poster presentation highlighting RapidVax at the World Vaccine & Immunotherapy Congress West Coast and World Antiviral Congress, November 30 to December 2, 2021.

Key Points: 
  • RapidVax is designed as a rapid programmable vaccine to target a comprehensive range of emerging biological threats.
  • This platform has the potential to shorten the timelines needed to develop and test novel vaccines against emerging infectious agents.
  • RapidVax aims to provide a proven, safe, vaccine strategy that can be quickly engineered and adapted to address emerging biological threats.
  • The emergence of COVID-19 variants, such as Omicron, further highlights the urgent need for a novel cellular vaccine platform designed to provide a rapid, safe, and effective response to biological threats.

Aravive to Participate in Fireside Chat at Piper Sandler 33rd Annual Virtual Healthcare Conference

Retrieved on: 
Monday, November 15, 2021
Cancer, Ovarian cancer, DABT, Conference, Company, GLOBE, Event, Tectonic evolution of the Aravalli Mountains, Therapy, Piper Sandler Companies, Clear cell renal cell carcinoma, Platinum, Webcast, Pharmaceutical industry

HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 December 2, 2021.

Key Points: 
  • HOUSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive, and Reshma Rangwala, M.D., Ph.D., Chief Medical Officer of Aravive, will participate in a virtual fireside chat at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29 December 2, 2021.
  • Aravives presentation will be available for viewing on November 22, 2021 at 10:00 AM ET.
  • Aravive will also participate in virtual one-on-one meetings on December 1, 2021.
  • This conference is being held virtually, and a live webcast will be accessible on the Events & Presentations page of www.aravive.com .

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma

Retrieved on: 
Friday, November 12, 2021
DNA replication, SITC, PK, Cancer, Private Securities Litigation Reform Act, Investor, PD, AXL, Clinical trial, European Commission, Terminology, Food, Ovarian cancer, Risk, Nivolumab, COVID-19, Forward-looking statement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, ID, Neoplasm, Annual general meeting, Company, Tectonic evolution of the Aravalli Mountains, Therapy, SEC, Clear cell renal cell carcinoma, Platinum, GAS6, Review, Communication, Royal commission, Survival, DNA, Patient, Fast Track, Pharmaceutical industry

HOUSTON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC). A subset of these data was included in a poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021.

Key Points: 
  • A webcast of the conference call will be available in the Investors section of the Aravive website at https://ir.aravive.com/ .
  • The open-label Phase 2 portion of the clinical trial is expected to enroll 55 patients across three parts.
  • Part A is expected to enroll approximately 25 patients and investigate batiraxcept 15 mg/kg in combination with cabozantinib in 2L+ ccRCC patients.
  • The Company is currently evaluating its lead therapeutic, batiraxcept (AVB-500), in a registrational Phase 3 trial in platinum resistant ovarian cancer, a Phase 1b/2 trial in second line plus, clear cell renal cell carcinoma, and a Phase 1b/2 trial in first-line treatment of pancreatic adenocarcinoma.

Liquidia to Participate in the Jefferies London Healthcare Conference

Retrieved on: 
Thursday, November 11, 2021
PAH, NASDAQ, GMT, LLC, Conference, GLOBE, Hypertensive emergency, Pulmonary hypertension, Pharmaceutical industry

MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer of Liquidia, will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare Conference being held November 16-19, 2021 .

Key Points: 
  • MORRISVILLE, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer of Liquidia, will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare Conference being held November 16-19, 2021 .
  • The fireside chat will be available to registered participants on-demand beginning at 8:00 a.m. GMT on November 18, 2021.
  • The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC.
  • Liquidia Technologies has developed YUTREPIA (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH).

Syneos Health to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 11, 2021
CRO, Contract research organization, GMT, Evercore, Conference, Company, CCO, GLOBE, Nasdaq, Patient, Fine chemical

ET

Key Points: 
  • ET
    A webcast of each event, along with an archived audio replay of each presentation, will be available on the Companys Investor Relations website at investor.syneoshealth.com .
  • Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization.
  • We bring together approximately 28,000 clinical and commercial minds with the ability to support customers in more than 110 countries.
  • To learn more about how we are Shortening the distance from lab to life, visit syneoshealth.com or subscribe to our podcast .

Heat Biologics Provides Third Quarter 2021 Business Update

Retrieved on: 
Wednesday, November 10, 2021
Safety, Maintenance, Cancer, Private Securities Litigation Reform Act, Contract, Form 10-K, Infection, NASDAQ, Immune system, Terminology, Growth, Investment, COVID-19, Research, Heat Biologics, Program, Sale, Annual report, Quality control, Company, GLOBE, Inflammation, SEC, Nasdaq, Time, Marketing, Patient, Scorpion, FDA, Pharmaceutical industry, Animal

DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NASDAQ: HTBX), today provided strategic, financial, and operational updates for the third quarter ended September 30, 2021.

Key Points: 
  • DURHAM, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NASDAQ: HTBX), today provided strategic, financial, and operational updates for the third quarter ended September 30, 2021.
  • Recognized $0.5 million of grant revenue for qualified expenditures under the CPRIT grant for the quarter ended September 30, 2021 compared to $0.8 million for the quarter ended September 30, 2020.
  • Net loss attributable to Heat Biologics was approximately $7.4 million, or ($0.30) per basic and diluted share for the quarter ended September 30, 2021 compared to a net loss of approximately of $8.9 million, or ($0.43) per basic and diluted share for the quarter ended September 30, 2020.
  • Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system.

Aravive Announces Positive Preliminary Data from Phase 1b Trial Evaluating Batiraxcept (AVB-500) in Combination with Cabozantinib in Clear Cell Renal Cell Carcinoma to be Presented at 2021 Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Tuesday, November 9, 2021
DNA replication, SITC, Progression-free survival, Cancer, Private Securities Litigation Reform Act, Investor, AXL, Clinical trial, European Commission, Terminology, Food, Ovarian cancer, Risk, COVID-19, Forward-looking statement, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Annual report, ID, Neoplasm, Annual general meeting, Company, Tectonic evolution of the Aravalli Mountains, Therapy, SEC, Clear cell renal cell carcinoma, Pharmacokinetics, Platinum, Webcast, Review, Communication, GAS6, Royal commission, Survival, DNA, Patient, Fast Track, Pharmaceutical industry

HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative, targeted therapeutics to treat life-threatening cancers, today announced that positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC) will be presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting on November 13, 2021. The presentation will highlight interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity data.

Key Points: 
  • The conference call may be accessed by dialing (877) 423-9813 (domestic) and (201) 689-8573 (international) and referring to conference ID 13724115.
  • A webcast of the conference call will be available in the Investors section of the Aravive website at https://ir.aravive.com/ .
  • Aravive initiated the Phase 1b portion of the Phase 1b/2 trial of batiraxcept in ccRCC in March 2021.
  • In doing so, batiraxcept selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types including ovarian, renal and pancreatic cancer.